These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26186129)

  • 1. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.
    Guihot A; Dentone C; Assoumou L; Parizot C; Calin R; Seang S; Soulié C; Marcelin AG; Calvez V; Autran B; Katlama C; Costagliola D; Carcelain G
    AIDS; 2016 Jan; 30(2):327-30. PubMed ID: 26186129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
    Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
    HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
    Allavena C; Rodallec A; Sécher S; Reliquet V; Baffoin S; André-Garnier E; Billaud E; Raffi F; Ferré V
    J Med Virol; 2013 Nov; 85(11):1878-82. PubMed ID: 23861166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
    Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
    Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
    Lim A; Tan D; Price P; Kamarulzaman A; Tan HY; James I; French MA
    AIDS; 2007 Jul; 21(12):1525-34. PubMed ID: 17630546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-7 signalling defects in naive CD4+ T cells of HIV patients with CD4+ T-cell deficiency on antiretroviral therapy are associated with T-cell activation and senescence.
    Tanaskovic S; Fernandez S; Price P; French MA
    AIDS; 2014 Mar; 28(6):821-30. PubMed ID: 24499954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
    Hunt PW; Brenchley J; Sinclair E; McCune JM; Roland M; Page-Shafer K; Hsue P; Emu B; Krone M; Lampiris H; Douek D; Martin JN; Deeks SG
    J Infect Dis; 2008 Jan; 197(1):126-33. PubMed ID: 18171295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1.
    Bouscarat F; Levacher-Clergeot M; Dazza MC; Strauss KW; Girard PM; Ruggeri C; Sinet M
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):17-24. PubMed ID: 8825614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection.
    Boyd A; Meynard JL; Morand-Joubert L; Michon A; Boccara F; Bastard JP; Samri A; Haddour N; Mallat Z; Capeau J; Desvarieux M; Girard PM;
    PLoS One; 2014; 9(11):e113876. PubMed ID: 25415323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
    Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE
    Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
    Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
    Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
    Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
    J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
    Rajasuriar R; Booth D; Solomon A; Chua K; Spelman T; Gouillou M; Schlub TE; Davenport M; Crowe S; Elliott J; Hoy J; Fairley C; Stewart G; Cameron P; Lewin SR
    J Infect Dis; 2010 Oct; 202(8):1254-64. PubMed ID: 20812848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.